> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Apotex Recalls 3 Lots of Guanfacine Extended-Release Tablets
- URL: https://www.fdaweb.com/apotex-recalls-3-lots-of-guanfacine-extended-release-tablets/
- Published: 2021-04-01T12:00:00.000Z
- Updated: 2026-09-14T16:53:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149025

FDA says Apotex is recalling three lots of Guanfacine extended-release tablets 2 mg due to trace amounts of Quetiapine fumarate in one lot. A company announcement published by FDA [says](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/apotex-corp-issues-voluntary-nationwide-recall-guanfacine-extended-release-tablets-2mg-due-trace?ref=fdaweb.com#recall-announcement) the administration of contaminated tablets can result in hypersensitivity reaction and may have additive effects in lowering blood pressure, sleepiness/sedation, and dizziness. Apotex says it has not received any reports of adverse events related to the recall.

Guanfacine is indicated for treating attention deficit hyperactivity disorder, the statement says, and can be used with other stimulant medications. Quetiapine is indicated for treating schizophrenia and other serious mental disorders.

The affected lots reportedly were distributed in the U.S. to wholesalers, distributors, warehousing chains, independent retail pharmacies, and retail buying groups.